stockrow
Saturday 7 November 2026
Export SPRY’s income statement to Excel — free account
ARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024.
- Revenue
- +16.0%
- EPS
- +30.8%
- Free cash flow
- +36.5%
- Total debt
- +138.5%
Quarter to September 2026, against a year earlier
2.79
0.14
+5.28%
Follow SPRY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
13.63 | 8.06 | 6.80 | 3.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(26.41) | (17.74) | (13.06) | (12.74) | |
P/B ratio |
10.05 | 13.01 | 63.58 | 0.00 | |
Price to Tangible BV |
11.51 | 16.92 | 0.00 | 0.00 | |
EV/Sales |
12.72 | 7.76 | 7.05 | 3.79 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.28) | (4.39) | (4.19) | (2.53) | |
EV/FCF |
(5.75) | (4.03) | (3.88) | (2.33) | |
Quick Ratio |
6.91 | 4.63 | 3.13 | 2.94 | |
Current Ratio |
7.28 | 4.94 | 3.48 | 3.25 | |
Net Debt/EBITDA |
1.82 | 0.49 | (0.45) | 0.00 | |
Debt/Assets |
51.43% | 59.53% | 68.78% | 0.00% | |
Debt/Equity |
1.47 | 2.79 | 13.72 | 0.00 | |
Asset Turnover |
0.25 | 0.32 | 0.42 | 0.39 | |
Operating CF/Net income |
1.05 | 0.74 | 0.98 | 0.00 | |
Capex/Depreciation |
3.41 | 0.00 | 0.00 | — | |
Interest Coverage |
— | (24.64) | (24.79) | — | |
Research and Development Expense of Revenue |
12.26% | 19.12% | 13.96% | 48.43% | |
Selling, General and Administrative Expense of Revenue |
213.46% | 318.35% | 230.49% | 115.41% | |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.06 | 0.05 | |
Share Based Compensation of Revenue |
20.43% | 32.73% | 36.83% | 21.54% | |
Graham Net Nets |
0.06 | 0.02 | (0.03) | (0.12) | |
Graham Number |
0.00 | 0.00 | 0.00 | 2.33 | |
Earnings Yield |
(15.02%) | (25.03%) | (27.22%) | (46.87%) | |
Free Cash Flow Yield |
(16.25%) | (23.93%) | (26.66%) | (46.26%) | |
Revenue per Share |
0.29 | 0.23 | 0.34 | 0.38 | |
Operating CF per Share |
(0.44) | (0.45) | (0.61) | (0.34) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.46) | (0.45) | (0.61) | (0.34) | |
Cash per Share |
2.49 | 2.02 | 1.45 | 1.39 | |
Shareholders Equity per Share |
1.16 | 0.62 | 0.13 | (0.12) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.16 | 0.62 | 0.13 | (0.12) | |
Free Cash Flow |
(45.48) | (44.95) | (60.93) | (33.71) | |
Working Capital |
245.75 | 195.62 | 150.65 | 146.13 | |
Capital Expenditures |
(2.00) | — | — | — | |
Net Current Asset Value |
71.50 | 18.97 | (25.47) | (52.41) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
16.76 | 18.98 | 35.98 | 44.60 | |
Average Payables |
30.39 | 37.64 | 52.00 | 56.78 | |
Average Inventory |
6.79 | 8.04 | 10.21 | — | |
Average Assets |
339.40 | 307.44 | 281.48 | 312.14 | |
Average Common Equity |
185.53 | 145.14 | 102.42 | 67.85 |
Columns are period end dates · fundamentals updated 5 Nov 2026